Savior Lifetec Corp

Savior Lifetec Corp maintains a strong liquidity position, with a current ratio of 11.06, indicating that the company has significantly more current assets than current liabilities. The company also holds TWD 588 million in cash and equivalents, which provides a buffer against short-term obligations. However, the operating cash flow is negative at TWD -21.04 million, suggesting that core operations are not currently generating positive cash flow. Profitability metrics are robust, with a return on equity (ROE) of 14.22% and a return on assets (ROA) of 12.84%. These figures exceed the typical thresholds for the pharmaceutical industry, indicating that the company is effectively utilizing its equity and asset base to generate returns. The gross profit margin stands at 35.24% (TWD 423.41 million gross profit on TWD 1.2 billion in revenue), which is in line with industry norms. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segmental and geographic detail limits the ability to assess exposure to regional market risks or growth opportunities. Looking ahead, the company is expected to maintain a stable revenue trajectory, with no significant growth or contraction projected in the current or next fiscal year. The capital expenditure of TWD -142.26 million indicates a reduction in investment in physical assets, which may reflect a strategic shift or a focus on cost optimization. Risk factors for the company are currently low, with no immediate liquidity or dilution concerns identified. The debt-to-equity ratio is 0.05, indicating a conservative capital structure with minimal reliance on debt financing. However, the negative operating cash flow raises questions about the sustainability of operations without external financing or cost adjustments. Recent filings and transcripts do not highlight any material events or strategic shifts that would significantly alter the company's trajectory. The company appears to be in a maintenance phase, with no major product launches or regulatory approvals disclosed in the latest available data.